1: Can J Ophthalmol. 2010 Feb;45(1):91-2. 

Macular thickening in acute anterior uveitis with a 6-month remission period.

Moreno-Arrones JP, Gorrono-Echebarria MB, Teus-Guezala MA.

Publication Types:
    Letter

PMID: 20130729  [PubMed - in process]

2: Can J Ophthalmol. 2010 Feb;45(1):90-1. 

Histoplasma capsulatum endophthalmitis in southeastern Ontario.

Leung C, Farmer JP, Zoutman DE, Urton TE, Gale JG.

Publication Types:
    Letter

PMID: 20130728  [PubMed - in process]

3: Can J Ophthalmol. 2010 Feb;45(1):89-90. 

Giant spontaneously regressed retinoblastoma.

Sinha N, Shields CL, Ramasubramanian A, Ferenczy S, Sheilds JA.

Publication Types:
    Letter

PMID: 20130727  [PubMed - in process]

4: Can J Ophthalmol. 2010 Feb;45(1):87-9. 

Intraocular framycetin sulphate ointment after sutureless clear corneal section
phacoemulsification.

Murjaneh S, Waqar S, Kumudhan D, Simcock PR, Jacob JH.

Publication Types:
    Letter

PMID: 20130726  [PubMed - in process]

5: Can J Ophthalmol. 2010 Feb;45(1):86-7. 

Cryptophthalmos associated with orbito-palpebral cysts: a case report.

Li XM, Song E, Song Y.

Publication Types:
    Letter

PMID: 20130725  [PubMed - in process]

6: Can J Ophthalmol. 2010 Feb;45(1):85-6. 

Merkel cell carcinoma of the eyelid: a report of 2 cases.

Bleyen I, Wong J, Nguyen Q, Blanc JP, Hardy I.

Publication Types:
    Letter

PMID: 20130724  [PubMed - in process]

7: Can J Ophthalmol. 2010 Feb;45(1):83-4. 

Regression of soft drusen and drusenoid pigment epithelial detachment following
intravitreal anti-vascular endothelial growth factor therapy.

Krishnan R, Lochhead J.

Publication Types:
    Letter

PMID: 20130723  [PubMed - in process]

8: Can J Ophthalmol. 2010 Feb;45(1):82-3. 

Vitritis and retinal vasculitis as presenting signs of monoclonal gammopathy of
unknown significance with progression to multiple myeloma.

Chan TY, Hodge WG.

Publication Types:
    Letter

PMID: 20130722  [PubMed - in process]

9: Can J Ophthalmol. 2010 Feb;45(1):81. 

Considering amyloidosis in patients with clinically unresponsive vitreous
inflammation (Oculoleptomeningeal amyloidosis in 3 individuals with
transthyretin variant Tyr69His. Vol. 44[3]).

Roe RH, Cunningham ET Jr.

Publication Types:
    Comment
    Letter

PMID: 20130721  [PubMed - in process]

10: Can J Ophthalmol. 2010 Feb;45(1):81-2. 

Osteoporosis prophylaxis prescribing patterns in ophthalmology patients treated
with long-term corticosteroids.

Walker RA, Hall RB, Pekush RD, Taylor-Gjevre RM.

Publication Types:
    Letter

PMID: 20130720  [PubMed - in process]

11: Can J Ophthalmol. 2010 Feb;45(1):80. 

Common variable immunodeficiency in pediatric neurosarcoidosis (protean
manifestations of pediatric neurosarcoidosis. Vol. 44[4]).

Gonzalez-Granado LI.

Publication Types:
    Comment
    Letter

PMID: 20130719  [PubMed - in process]

12: Can J Ophthalmol. 2010 Feb;45(1):79; author reply 79-80. 

Awareness of industry bias (management of dysfunctional tear syndrome: a
Canadian consensus. Vol. 44[4]).

Giligson A.

Publication Types:
    Comment
    Letter

PMID: 20130718  [PubMed - in process]

13: Can J Ophthalmol. 2010 Feb;45(1):76-8. 

Mucinous eccrine adenocarcinoma of the eyelid: report of 6 cases.

Zhang Q, Wojno TH, Fitch SD, Grossniklaus HE.

Departments of Ophthalmology, Emory University School of Medicine, Atlanta, GA
30322, USA.

OBJECTIVE: To report on patients with mucinous eccrine adenocarcinoma of the
eyelid. DESIGN: Retrospective case series. PARTICIPANTS: Biopsy specimens of 6
patients with eyelid neoplasm were obtained. The pathologic diagnoses were
mucinous eccrine adenocarcinomas. METHODS: The medical records, including
demographic, clinical, histopathologic, and follow-up information, were
reviewed. RESULTS: Five patients underwent surgical removal of the lesion by
means of Mohs micrographic surgery. Four of these patients were doing well; 1 of
them, with positive margins of resection, had 2 recurrences. One case was lost
to follow-up. CONCLUSIONS: Mucinous eccrine adenocarcinoma is an uncommon
adnexal tumour that can involve the eyelid, has low metastasis and mortality,
but can be invasive or locally recur. Mohs micrographic surgery is a recommended
treatment of mucinous eccrine adenocarcinoma of the eyelid.

Publication Types:
    Research Support, Non-U.S. Gov't

PMID: 20130716  [PubMed - in process]

14: Can J Ophthalmol. 2010 Feb;45(1):71-5. 

Intravenous immunoglobulin in recurrent-relapsing inflammatory optic neuropathy.

Stiebel-Kalish H, Hammel N, van Everdingen J, Huna-Baron R, Lee AG.

Neuro-Ophthalmology Unit, Department of Ophthalmology, Rabin Medical Center,
Petah Tikva, Israel. kalishh@clalit.org.il

OBJECTIVE: Recurrent-relapsing inflammatory optic neuropathy, including chronic
relapsing inflammatory and autoimmune optic neuropathies, is rare, but can cause
severe visual loss. Long-term steroids may preserve vision, yet side effects are
frequent. We describe our experience with intravenous immunoglobulins (IVIg).
DESIGN: A semi-prospective case series from 4 medical centres. PARTICIPANTS:
Patients with steroid responsive recurrent-relapsing optic neuropathy. METHODS:
Semiprospective case series of IVIg treatment in steroid-responsive
recurrent-relapsing optic neuropathy at 4 medical centres. Outcome measures
included visual outcome; time to, and duration of, remission; duration of
corticosteroid use; and adverse events. RESULTS: Vision stabilized in all 6
patients treated with IVIg without steroids for extended periods of time. None
improved and none worsened. One adverse event occurred during an IVIg infusion
after 3 uneventful years of IVIg maintenance. Average steroid use prior to IVIg
was 12 months. After IVIg treatment, 5/6 patients no longer required
corticosteroids. Two patients experienced late relapses on IVIg, one of whom was
treated with cyclosporine, the other with steroids. CONCLUSIONS: IVIg can be
considered an effective steroid-sparing agent in selected cases with
steroid-dependent recurrent-relapsing autoimmune optic neuropathy.

PMID: 20130715  [PubMed - in process]

15: Can J Ophthalmol. 2010 Feb;45(1):67-70. 

Changes in corneal thickness, curvature, and anterior chamber depth during the
menstrual cycle.

Hashemi H, Mehravaran S, Rezvan F.

Noor Ophthalmology Research Center, Noor Eye Hospital; and the Farabi Eye
Hospital, Tehran University of Medical Sciences, Tehran,Iran.

OBJECTIVE: To determine the variations in corneal thickness values, keratometry
readings, and anterior chamber depths (ACD) during the menstrual cycle of young
women using the noncontact Scheimpflug imaging technique. DESIGN: Prospective
cohort study. PARTICIPANTS: Fourteen women with regular menstrual cycles who
were not taking contraceptive pills were enrolled and had measurements taken
every other day during a full menstrual cycle, starting from the first day. None
used contact lenses or regular medication, and none had systemic disease or
history of eye surgery. METHODS: The thickness at the centre, superior,
inferior, temporal, nasal, and thinnest point of the cornea, the keratometry
readings, and the ACD values measured with the Pentacam were recorded. We used
data on days 1, 3, and 5 of the studied cycle, and counting backwards, 2, 4, 6,
12, 14, and 16 days before the first day of the next cycle. RESULTS: The mean
differences between 2 points of time were not statistically significant (p >
0.05) for any variable. The mean difference between any 2 paired thickness
measurements was less than 5.0 microm. CONCLUSIONS: Contrary to our expectations
and previous findings using ultrasound pachymetry, we found no clinically or
statistically significant differences between the repeated measurements with the
Pentacam. This could indicate that the Pentacam is a clinical tool with less
variability when performing serial measurements and follow-up examinations.

PMID: 20130714  [PubMed - in process]

16: Can J Ophthalmol. 2010 Feb;45(1):62-6. 

Concept of a functional retinal locus in age-related macular degeneration.

Shima N, Markowitz SN, Reyes SV.

Low Vision Service (University Health Network Hospitals), Department of
Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario,
Canada.

PURPOSE: Preferred retinal loci used for eccentric fixation in patients with
age-related macular degeneration (AMD) may be different from the eccentric
neighbouring loci of highest retinal sensitivity. This study was designed to
highlight the conceptual difference between the 2 and the concept of a
functional retinal locus encompassing both the preferred retinal locus and the
locus with highest retinal sensitivity. DESIGN: Prospective, nonrandomized,
observational case series. PARTICIPANTS: We recruited 15 adults with documented
AMD, low vision, and best-corrected visual acuity of 20/50-20/400 in the better
eye. METHODS: Automated microperimetry methods were used to assess topographic
retinal sensitivity and location of preferred retinal loci. RESULTS: Mean (SD)
age for the group was 85.1 (6.5) years. Mean (SD) best-corrected visual acuity
measured was 0.88 (0.25) logMar units (20/150). The mean (SD) eccentricity of
the preferred retinal locus used for fixation was different from the
eccentricity of the area with highest retinal sensitivity in the same eye (7.53
degrees [2.47 degrees ] vs 9.30 degrees [2.93 degrees ], respectively; p <
0.0003). The oculomotor efficiency score measured 82%. The mean (SD) retinal
sensitivity at the preferred retinal loci was inferior to that of loci with
highest retinal sensitivity (5.83 [4.26] vs 8.60 [3.06] dB, respectively; p <
0.0007). The highest correlation was measured between potential visual acuity
estimates and estimates of retinal sensitivity at the highest retinal
sensitivity loci (p < 0.0048). CONCLUSIONS: Preferred retinal loci and highest
retinal sensitivity loci are not identical in AMD cases. A new concept of
functional retinal locus is proposed to define their relation. A new concept of
an oculomotor efficiency score is proposed to define oculomotor abilities when
macular function is lost.

Publication Types:
    Research Support, Non-U.S. Gov't

PMID: 20130713  [PubMed - in process]

17: Can J Ophthalmol. 2010 Feb;45(1):58-61. 

The relationship between scotoma displacement and preferred retinal loci in
low-vision patients with age-related macular degeneration.

Markowitz SN, Aleykina N.

Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto,
Ontario, Canada. snm1@rogers.com

OBJECTIVE: Adaptive strategies in low-vision patients with age-related macular
degeneration use preferred retinal loci (PRLs) for the purpose of achieving
better visual function. In the process of redirecting the eye toward the PRL,
central scotomata are displaced eccentrically. The consequential effect of the
first on the second may offer an indirect method for PRL identification. The
purpose of this study was to clarify the relationship between scotoma
displacement and PRL location. DESIGN: Prospective, nonrandomized, observational
case series. PARTICIPANTS: Forty-one adults with a confirmed diagnosis of
age-related macular degeneration. METHODS: Scotoma characteristics were obtained
with automated perimetry. PRL topography was obtained with the Nidek MP-1
instrument. Outcome measures selected for this study were scotoma displacement
and PRL eccentricities estimates. RESULTS: We tested 16 males and 25 females
aged 70-98 years (mean 82.5 [SD 6.71] years) with best-corrected visual acuity
of 0.81 (SD 0.24) logMar units (20/128). PRL location logically matched scotoma
displacement in 30 study subjects (73.17%, p < 0.00432). In this subgroup (n =
30), PRL eccentricity (5.55 [SD 3.35] degrees ) was almost identical to scotoma
displacement eccentricity (5.22 [SD 1.98] degrees )(p < 0.65). CONCLUSIONS:
Scotoma displacement recorded with macular perimetry methods offers reasonable
indirect estimates of PRL location.

PMID: 20130712  [PubMed - in process]

18: Can J Ophthalmol. 2010 Feb;45(1):52-7. 

The effect of combined topical-intracameral anaesthesia on neuroleptic
requirements during cataract surgery.

Ho AL, Zakrzewski PA, Braga-Mele R.

University of British Columbia Medical School, Vancouver, BC, Canada.

OBJECTIVE: To evaluate whether the addition of intracameral lidocaine to topical
anaesthesia during cataract surgery leads to a decrease in the administration of
intraoperative midazolam and fentanyl. DESIGN: Retrospective case-control study.
PARTICIPANTS: The eyes of 124 patients undergoing phacoemulsification were
included in the study, with 62 in the intracameral group and 62 in the control
group. METHODS: A single-centre, retrospective chart review of cases between
April and October 2007 in which patients had undergone small-incision
phacoemulsification with foldable intraocular lens insertion and received
preoperatively either topical tetracaine 0.5% with unpreserved intracameral
lidocaine 1% (intracameral group) or topical tetracaine 0.5% alone (control
group). Intraoperatively, midazolam and fentanyl were administered as needed
based on pain and anxiety. RESULTS: A total of 124 eyes (124 patients) were
included. There was no statistically significant difference between the mean
intraoperative midazolam doses given for the 2 groups (p = 0.08). The mean
intraoperative dose of fentanyl was lower in the intracameral than in the
control group (p < 0.0001). A comparison of intraoperative fentanyl requirements
between groups using a multivariate regression analysis for age, gender,
surgical time, and preoperative fentanyl levels confirmed the lower need for
intraoperative fentanyl in the intracameral compared with the control group (p =
0.0037). There were no anaesthetic complications among any of the study
patients. CONCLUSIONS: Patients receiving topical tetracaine 0.5% with
unpreserved intracameral lidocaine 1% during cataract surgery demonstrated a
reduction in intraoperative fentanyl requirements. Surgeons performing cataract
surgery under topical anaesthesia should consider the addition of intracameral
lidocaine 1% to decrease fentanyl requirements and improve patient safety and
comfort.

Publication Types:
    Research Support, Non-U.S. Gov't

PMID: 20130711  [PubMed - in process]

19: Can J Ophthalmol. 2010 Feb;45(1):46-51. 

Retinal heparanase expression in streptozotocin-induced diabetic rats.

Ma P, Luo Y, Zhu X, Li T, Hu J, Tang S.

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
University, Guangzhou, China.

OBJECTIVE: Heparanase, an endoglycosidase, exhibits strong proangiogenic
capacity that can induce vascular endothelial growth factor (VEGF) expression in
tumour angiogenesis. The purpose of this study was to evaluate heparanase
expression and its relationship with VEGF in streptozotocin (STZ)-induced
diabetic rats' retinas. DESIGN: Experimental study. PARTICIPANTS: STZ-induced
rats and non-diabetic control rats. METHODS: Heparanase expression was initially
evaluated in cultured human retinal microvascular endothelial cells (HRECs)
under high-glucose conditions by Western blot. Diabetes was induced in
Sprague-Dawley rats by STZ intraperitoneal injection. Retinal heparanase
expression was assayed in rats by immunohistochemistry. Heparanase inhibitor
(phosphomannopentaose sulfate) was administrated to high-glucose-treated HRECs
and diabetic rats. VEGF levels were evaluated in HRECs and retinas using
enzyme-linked immunosorbent assay. RESULTS: Heparanase expression was increased
in HRECs under high-glucose conditions compared with controls (p < 0.01).
Immunohistochemical studies indicated that heparanase signals were intense in
the retinal vascular endothelia of diabetic rats, but faint in those of
nondiabetic control rats. Quantitative analysis showed that heparanase protein
expression was increased by 3.2-fold in diabetic rats' retinas compared with
nondiabetic rats' retinas (p < 0.01). VEGF level was increased, as was
heparanase expression, in high-glucose-treated HRECs and in the retinas of
diabetic rats, and these increases were significantly decreased by
phosphomannopentaose sulfate administration (p < 0.01). CONCLUSIONS: Heparanase
expression was upregulated and associated with an increase of VEGF expression in
STZ-induced diabetic rat retinas. The data suggest that heparanase may be
involved in the development of diabetic retinopathy and represents a possible
novel target for therapeutic intervention.

Publication Types:
    Research Support, Non-U.S. Gov't

PMID: 20130710  [PubMed - in process]

20: Can J Ophthalmol. 2010 Feb;45(1):41-5. 

The effect of oral acetazolamide on weight gain in children.

Sharan S, Dupuis A, Hebert D, Levin AV.

Ivey Eye Institute, London Health Sciences Centre, University of Western
Ontario, London, Ontario, Canada.

OBJECTIVE: Oral acetazolamide is a potent medical treatment for pediatric
glaucoma, but ophthalmologists may have concerns that it retards weight gain in
children and may choose surgical management instead. DESIGN: Retrospective chart
review. PARTICIPANTS: Twenty-two well children with glaucoma taking
acetazolamide orally for >or=3 months. METHODS: Abnormal weight gain was
determined using downward crossing of 2 percentile lines on growth charts and
change in z score for weight using a hierarchical linear model. RESULTS: One
patient with Sturge-Weber syndrome and growth failure was excluded when growth
hormone deficiency was diagnosed. Two patients crossed 2 lines downward; both
showed metabolic acidosis. The trend for the 2 reversed after medication was
discontinued. The other 20 tracked steadily on growth curves. Eleven patients
(11/22, 50%) showed a decline in z score for weight over the follow-up period,
and the remainder showed an increase, for an overall estimate of slope in this
sample of 0.01, which was not significant (p = 0.8). CONCLUSIONS: Oral
acetazolamide may cause poor weight gain in a small subset of children on
treatment. Metabolic acidosis may be a mediating factor for growth failure. Our
data suggest that acetazolamide does not cause significant weight changes in
cases of pediatric glaucoma. Growth parameters should be followed. Growth
hormone deficiency should be considered in Sturge-Weber syndrome. Prospective
study is needed.

Publication Types:
    Research Support, Non-U.S. Gov't

PMID: 20130709  [PubMed - in process]

21: Can J Ophthalmol. 2010 Feb;45(1):36-40. 

Triple therapy for neovascular age-related macular degeneration (verteporfin
photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab).

Ehmann D, Garcia R.

Pasqua Hospital Eye Centre, University of Saskatchewan, Regina, Sask., Canada.

OBJECTIVE: Age-related macular degeneration is a multifactorial disease
involving inflammation, neovascularization, and vascular leakage. As a result, a
rationale exists for investigating combination treatments that target the
different pathological processes involved in this disease. We propose triple
therapy consisting of verteporfin photodynamic therapy (PDT), intravitreal
bevacizumab, and intravitreal dexamethasone. DESIGN: Retrospective chart review.
PARTICIPANTS: Thirty-two eyes of 30 patients were included. None of the patients
demonstrated concurrent eye pathology, and none of the patients had received
previous treatment for their choroidal neovascularization. METHODS: One cycle of
triple therapy consisted of reduced-fluence PDT (300 mW/cm(2) for 83 seconds to
deliver 25 J/cm(2)) followed immediately by an 800 microg (0.08 mL) intravitreal
dexamethasone (IVD) injection. At 1 and 7 weeks after PDT and IVD, patients
received a 1.25 mg (0.05 mL) bevacizumab injection. At 13 weeks after PDT and
IVD, each patient had a repeat optical coherence tomography and fluorescein
angiography to assess choroidal neovascularization activity. Patients were
followed for 12 months. RESULTS: The mean number of treatment cycles was 1.4.
The mean number of bevacizumab injections was 2.8. Visual acuity improved from
0.74 (SD 0.33) logMAR (20/100) to 0.53 (SD 0.32) logMAR (20/70) (p < 0.005).
Foveal thickness decreased from 328 (SD 116) microm to 216 (SD 85) microm (p <
0.001). Ninety-four percent of patients lost fewer than 3 lines, 31% gained more
than 3 lines, and 6% lost more than 3 lines. CONCLUSIONS: By combining agents
with complementary mechanisms of action, triple therapy could maintain visual
acuity and macular anatomy while allowing a reduction in the number of
anti-vascular endothelial growth factor injections required.

PMID: 20130708  [PubMed - in process]

22: Can J Ophthalmol. 2010 Feb;45(1):33-5. 

Patency of superior ciliary sulcus in aphakic silicone oil-filled eyes: an
ultrasound biomicroscopy study.

Soliman MM, Macky TA.

Diagnostic Laser Unit, Department of Ophthalmology, Kasr El Aini Hospital, Cairo
University, El-Manial, Cairo, Egypt.

OBJECTIVE: To assess the patency of the superior ciliary sulcus in aphakic
silicone oil-filled eyes by ultrasound biomicroscopy (UBM). DESIGN: Prospective
interventional series. PARTICIPANTS: Twelve eyes of 12 patients were included in
this study. METHODS: Twelve aphakic silicone oil-filled eyes were evaluated
using UBM. The UBM examination of the anterior segment was performed using the
Humphrey Instruments UBM equipped with a high-frequency (50 MHz),
high-resolution (50 microm) transducer. The patients were placed in a
semisitting position in which their backs were inclined to a suitable angle
(about 50 degrees ). They were also asked to look straight ahead, to bring the
superior ciliary sulcus to the highest point of the globe. The probe approached
the patients' eyes superiorly at a slight angle (about 10 degrees ). Images of
the superior ciliary sulcus were captured and analyzed. RESULTS: The UBM images
demonstrated an intact curved aqueous-silicone oil interface that appeared at
some distance from and not filling the ciliary sulcus. A patent superior ciliary
sulcus was thus found in all patients, even in those with a widely opened
ciliary sulcus. CONCLUSIONS: The superior ciliary sulcus maintained its patency
in aphakic silicone oil-filled eyes. These findings indicate that an iridectomy
in a superior position may also be effective, although this has not been tested
clinically in this report.

PMID: 20130707  [PubMed - in process]

23: Can J Ophthalmol. 2010 Feb;45(1):28-32. 

The prevalence of diabetic retinopathy as identified by teleophthalmology in
rural Alberta.

Nathoo N, Ng M, Rudnisky CJ, Tennant MT.

Faculty of Medicine and Dentistry, University of Alberta,Edmonton, Alberta,
Canada.

OBJECTIVE: The purpose of this study was to assess the prevalence of diabetic
retinopathy (DR) as identified by teleophthalmology in a sample population of
people with diabetes living in rural Alberta and to identify the risks and
benefits of a teleophthalmology program for these patients. DESIGN:
Retrospective consecutive case series. PARTICIPANTS: Three hundred ninety-four
diabetic patients (788 eyes). METHODS: Medical histories were obtained,
following which patients underwent visual acuity and intraocular pressure
measurements and stereoscopic, 7-field, digital retinal photography. Images were
graded by ophthalmologists in Edmonton, Alta., according to a modified Early
Treatment Diabetic Retinopathy Study scoring template. Diagnosis, treatment, and
follow-up recommendations were communicated to local health care providers and
data were collected for review. RESULTS: Three hundred ninety-four patients (788
eyes) were assessed via 593 teleophthalmology visits over the 3-year period. DR
was identified in 27.2% of patients (2.3% with proliferative DR and 24.9% with
nonproliferative DR). A variety of other diagnoses, independent of DR, were also
made. Recommendations for follow-up teleophthalmology and in-person referral
were completed in 76.8% and 87.3% of patients, respectively, although many were
completed later than was recommended. Teleophthalmology saved approximately 450
round trips from Edson to the nearest urban centre (Edmonton) over the 2-year
period, equating to approximately 1900 hours and 180 000 km of driving.
CONCLUSIONS: Teleophthalmology can effectively identify DR while reducing travel
time and distance for patients with diabetes living in a rural community.
However, many patients did not follow up or attend referral appointments in a
timely fashion, underscoring the need for ongoing quality assessment.

Publication Types:
    Research Support, Non-U.S. Gov't

PMID: 20130706  [PubMed - in process]

24: Can J Ophthalmol. 2010 Feb;45(1):22-7. 

A genetic approach to stratification of risk for age-related macular
degeneration.

Zanke B, Hawken S, Carter R, Chow D.

vision of Epidemiology, Ottawa Health Research Institute, Ottawa, Ontario,
Canada. brent.zanke@ohri.ca

The genetic determinants of age-related macular degeneration (AMD) are reviewed
and a novel approach to risk determination based upon inherited genetic
polymorphisms and smoking history is presented. Although AMD was long thought to
have primarily an environmental etiology, genetic variation is now known to
account for the majority of the disease risk, with variations in the genes of
the complement pathways playing a prominent role. Independent and validated
clinical studies have implicated the C3 gene and its regulator, complement
factor H (1q31.1), complement component 2 (6q21.33), and complement factor B
(6q21.33). Subtle variations in complement activity increase the risk of
symptomatic macular inflammation with age. A second group of AMD-associated
genetic markers may aggravate complement-mediated inflammation by permitting
retinal oxidative damage. Variation within the chromosomal site (10q26) coding a
mitochondrial-associated protein (age-related maculopathy susceptibility 2) and
an independent variation within the mitochondrial genome itself (A4917G) suggest
a contributing pathophysiological role of retinal oxidative stress. A genetic
panel of disease-susceptibility markers and smoking history can identify a group
of individuals with greater than 65% lifetime risk of AMD. The introduction of
genetic marker testing into clinical practice may identify patients with early
disease who may be aided by presymptomatic monitoring or inclusion into trials
of newer prophylactic agents.

PMID: 20130705  [PubMed - in process]

25: Can J Ophthalmol. 2010 Feb;45(1):17-21. 

[In Process Citation]

[Article in French]

Beral L, Richer R, Donnio A, Merle H.

Service d'Ophtalmologie, Centre Hospitalier Universitaire de Fort-de-France,
Hopital Pierre Zobda-Quitman, Fort-de-France Cedex, Martinique, France.
laurenceberal@hotmail.com

OBJECTIVE: The purpose of this study is to suggest an alternative surgery to
mutilating exenteration and enucleation surgeries in the management of
nonfunctional, unattractive, and painless eyes. The suggested alternative is
lamellar keratectomy with conjunctiva recovery. DESIGN: Retrospective study.
PARTICIPANTS: Four patient cases in a unit with the benefit of this technique.
METHODS: The surgical processes and results of the four cases were reviewed.
RESULTS: Postoperative results were most satisfactory with good esthetic results
and, above all, a better psychological experience of surgery. CONCLUSIONS: For a
nonfunctional, unattractive, and painless eye, lamellar keratectomy with
conjunctiva recovery appears to be an appealing alternative to nonconservative
eyeball surgeries.

Publication Types:
    English Abstract

PMID: 20130704  [PubMed - in process]

26: Can J Ophthalmol. 2010 Feb;45(1):10-2. 

Prevention of steroid-induced osteoporosis is not unique to ophthalmology.

Pope J, McKeown E.

Publication Types:
    Editorial

PMID: 20130702  [PubMed - in process]

27: Can J Ophthalmol. 2010 Feb;45(1):9-10. 

Evisceration, enucleation, and alternatives to globe removal.

Dolman PJ.

Publication Types:
    Editorial

PMID: 20130701  [PubMed - in process]

28: Can J Ophthalmol. 2009 Dec;44(6):e67. 

[In Process Citation]

[Article in French]

Olfa G, Riadh H, Sameh T, Fafani BH, Slim BA.

Publication Types:
    Letter

PMID: 20052002  [PubMed - in process]

29: Can J Ophthalmol. 2009 Dec;44(6):e65. 

Trichomegaly secondary to erlotinib.

Desai RU, Rachakonda LP, Saffra NA.

Publication Types:
    Letter

PMID: 20052001  [PubMed - in process]

30: Can J Ophthalmol. 2009 Dec;44(6):e63. 

A case of superficial corneal tattooing for glare after trabeculectomy.

Ahn SJ, Han YK, Kwon JW.

Publication Types:
    Letter

PMID: 20052000  [PubMed - in process]